Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients?

OBJECTIVE: We aim to investigate whether the use of dipeptidyl peptidase inhibitors (DPP-4i) affects the severity of disease, hospital mortality, and 3-month post-discharge mortality in type 2 diabetes mellitus (T2DM) individuals with coronavirus disease 2019 (COVID-19) infection. METHODS: The study...

Descripción completa

Detalles Bibliográficos
Autores principales: Erol, Rumeysa Selvinaz, Sen, Esra Cil, Ozturk, Feyza Yener, Sarac, Zeynep, Kokoglu, Gizem Leyla, Canat, Muhammed Masum, Yildiz, Duygu, Aytekin, Yunus Emre, Sevgi, Dilek Yildiz, Altuntas, Yuksel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464847/
https://www.ncbi.nlm.nih.gov/pubmed/36199855
http://dx.doi.org/10.14744/nci.2022.34341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464847/
https://www.ncbi.nlm.nih.gov/pubmed/36199855
http://dx.doi.org/10.14744/nci.2022.34341

Ejemplares similares